Shellie.....I don't recall you mentioning, but molecular testing had to show a tumor with a FGFR genetic alteration.
Patty's study: A Phase II, Single Arm Study of BGJ398 in patients with advanced cholangiocarcinoma is not open for accrual. In fact, it has discontinued. Current patients on this study will complete the trial.
Novartis is conducting another study for solid tumors (not specifically advanced cholangiocarcinoma) but with same FGFR alteration:
It is recruiting in a few States only:
Horizon Oncology Research, Inc.
Lafayette, Indiana, United States, 47905
Principal Investigator: Wael Harb
United States, New Mexico
New Mexico Cancer Care Alliance Oncology Dept Recruiting
Albuquerque, New Mexico, United States, 87106
Principal Investigator: Melanie Royce
Carolina Oncology Specialists, PC Recruiting
Hickory, North Carolina, United States, 28602
Principal Investigator: Richard Orlowski
Northwest Cancer Specialists Northwest Cancer
Portland, Oregon, United States, 97210
Principal Investigator: David A. Smith
United States, Washington
Providence Regional Cancer Partnership Providence Reg. Cancer (2)
Everett, Washington, United States, 98201
Principal Investigator: Jason Lukas
MultiCare Health System Institute for Research & Innovation MultiCare - Gig Harbor Recruiting
Tacoma, Washington, United States, 98405
Principal Investigator: John A. Keech